US District Judge Beryl Howell in Minneapolis denied Ranbaxy's request, the court filing showed.
While the UN report said that FDI inflows rose 6 per cent in 2018 to $ 42 billion, the government's own data for the entire FY19 period has shown that inbound equity investments declined for the first time in six years in FY19.
Sun Pharma stated the company wanted shareholders' approval to "issue, offer and allot equity shares or non-convertible securities, other than warrants, up to an amount of Rs 12,000 crore ($2 billion), to qualified institutional buyers pursuant to a QIP."
Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga
'When you have surplus cash flow and markets correct sharply, what options do you have other than buying good stocks?'
Nearly 150 senior management staff will be asked to leave.
Ranbaxy drugs sold in the United States will be gradually rebranded as Sun Pharma treatments
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
IT major TCS worst hit; it's m-cap slumped by Rs 11,811.13 cr to Rs 4,92,042.26 cr
A key lesson for the pharmaceutical sector in this case is to not downplay the significant impact that regulatory non-compliance can have on operations.
India seeks greater market access for its products including textiles, pharmaceuticals and bovine meat.
In the ranking of top-10 firms, TCS stood at number one position
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The FDA has been tightening its monitoring of Indian pharma majors over compliance issues. Surprise plant inspections and import alerts have been frequent outcomes
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The recalled drug bottles were distributed by Caraco Pharmaceutical Laboratories, Ltd in the US while manufactured in India by Sun Pharmaceutical Industries Ltd.
The Halol facility is important for the company as it accounts for 10 per cent of Sun Pharma's sales.
In March, the FDA had issued an import alert, banning formulations and active pharmaceutical ingredients from the factory.
The rupee recovered from more-than three months low of 63.15 in early trade on dollar selling by banks.
It had posted net profit of Rs 125.75 crore (Rs 1.25 billion) during the January-March quarter of the previous fiscal, 2012-13.
Two individuals filed the petition in the high court of Andhra Pradesh
At the start of 2016, HDFC Bank, Infosys, ICICI Bank, L&T and Axis Bank were the top five picks of fund managers
The recalled drugs were manufactured and distributed in the US by Ohm Laboratories.
Rosier year-end seen for Indian pharma thanks to faster US approvals.
Company aims to build five Rs 100 cr-plus brands and launch products from South African arm in domestic market
The group is looking into a new role for Ranbaxy CEO and MD Arun Sawhney.
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
Sun Pharma and Dr Reddy's top list in terms of those who face most class-action litigation
Who is to take their place? Will a new generation of entrepreneurs start up with better business sense, or at least better luck? But the so-called unicorns are mostly copy-cat entrepreneurs whose cash flow is funded by overseas (including Chinese) money, notes T N Ninan.
The m-cap of ONGC dipped Rs 13,303.78 crore, while that of Infosys tanked Rs 12,162.32 crore
Sun Pharma open to large acquisitions post Ranbaxy.
The merger has fortified Sun Pharma's position.
Sun Pharma profit down 30% over compliance costs, lower sales.
The Hinduja Group, Mukesh Ambani, Murugappa, and the Adani groups were the other gainers in the Modi regime, while Naveen Jindal and Sun Pharma groups saw the most erosion in their m-cap in the last five years, reports Krishna Kant.
Data late on Wednesday showed consumer price inflation eased more than-expected to a 25-month low of 8.10 per cent in February, while industrial output unexpectedly expanded, albeit only by 0.1 per cent.
Is yet to decide about the partnership or acquisition route
.jpg)
ITC, TCS and HDFC Bank emerged as the biggest gainers during the period.
FDA had cancelled Ranbaxy's approvals to launch generic Nexium, Valcyte
As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore.
Competition watchdog says 'high market concentration' in some segments a worry.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances